Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-induced Pneumonitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Immune checkpoint inhibitors (ICI) and targeted small-molecule drugs are mainstay elements of lung cancer chemotherapy. However, they are associated with development of pneumonitis, a rare, but potentially life-threatening event. We analyzed lung cancer patients treated with ICI to evaluate the effect of sequential therapeutic administration on the incidence of pneumonitis. Materials and Methods In this retrospective study, 242 patients were included. Serial radiologic findings taken during and immediately after ICI treatment were reviewed. Factors that increased pneumonitis and the relationship between peri-ICI chemotherapy and the development of pneumonitis were evaluated. Results Pneumonitis developed in 23 patients (9.5%); severe pneumonitis (grade ≥ 3) occurred in 13 of 23 patients (56%); pneumonitis-related death occurred in six. High-dose thoracic radiation (≥ 6,000 cGy) revealed a tendency toward high risk of pneumonitis (odds ratio, 2.642; 95% confidence interval, 0.932 to 7.490; p=0.068). Among 149 patients followed for ≥ 8 weeks after the final ICI dose, more patients who received targeted agents within 8-weeks post-ICI experienced pneumonitis (3/16, 18.8%) compared with patients who received cytotoxic agents (4/54, 7.4%) or no chemotherapy (4/79, 5.1%) (p=0.162). Targeted therapy was associated with earlier-onset pneumonitis than treatment with cytotoxic agents (35 vs. 62 days post-ICI, p=0.007); the resulting pneumonitis was more severe (grade ≥ 3, 100% vs. 0%, p=0.031). Conclusion Sequential administration of small-molecule targeted agents immediately after ICI may increase the risk of severe pneumonitis. The sequence of chemotherapy regimens that include ICI and targeted agents should be carefully planned to reduce the risk of pneumonitis in lung cancer patients.
Abstract
Purpose Immune checkpoint inhibitors (ICI) and targeted small-molecule drugs are mainstay elements of lung cancer chemotherapy. However, they are associated with development of pneumonitis, a rare, but potentially life-threatening event. We analyzed lung cancer patients treated with ICI to evaluate the effect of sequential therapeutic administration on the incidence of pneumonitis. Materials and Methods In this retrospective study, 242 patients were included. Serial radiologic findings taken during and immediately after ICI treatment were reviewed. Factors that increased pneumonitis and the relationship between peri-ICI chemotherapy and the development of pneumonitis were evaluated. Results Pneumonitis developed in 23 patients (9.5%); severe pneumonitis (grade ≥ 3) occurred in 13 of 23 patients (56%); pneumonitis-related death occurred in six. High-dose thoracic radiation (≥ 6,000 cGy) revealed a tendency toward high risk of pneumonitis (odds ratio, 2.642; 95% confidence interval, 0.932 to 7.490; p=0.068). Among 149 patients followed for ≥ 8 weeks after the final ICI dose, more patients who received targeted agents within 8-weeks post-ICI experienced pneumonitis (3/16, 18.8%) compared with patients who received cytotoxic agents (4/54, 7.4%) or no chemotherapy (4/79, 5.1%) (p=0.162). Targeted therapy was associated with earlier-onset pneumonitis than treatment with cytotoxic agents (35 vs. 62 days post-ICI, p=0.007); the resulting pneumonitis was more severe (grade ≥ 3, 100% vs. 0%, p=0.031). Conclusion Sequential administration of small-molecule targeted agents immediately after ICI may increase the risk of severe pneumonitis. The sequence of chemotherapy regimens that include ICI and targeted agents should be carefully planned to reduce the risk of pneumonitis in lung cancer patients.
참고문헌 (30)
- Lonberg N, "Masterful antibodies : checkpoint blockade", Cancer Immunol Res, 5, pp.275~281 (2017)
- Tolcher AW, "Phase Ib study of utomilumab(PF-05082566), a 4-1BB", CD137 agonist, in combination with pembrolizumab(MK-3475)in patients with advanced solid tumors, 2017, pp.23, 5349~5357
- Azzoli CG, "American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-smallcell lung cancer", J Clin Oncol, 27, pp.6251~6266 (2009)
- Ardizzoni A, "Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer : an individual patient data meta-analysis", J Natl Cancer Inst, 99, pp.847~857 (2007)
- Azzoli CG, "Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed", J Natl Cancer Inst, 99, pp.828~829 (2007)
- Shi Y, "A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-smallcell lung cancer of adenocarcinoma histology(PIONEER)", J Thorac Oncol, 9, pp.154~162 (2014)
- Soria JC, "Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
- Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Ma K, "The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer : a meta-analysis", Front Pharmacol, 9, pp.1430~ (2018)
- Skeoch S, "Drug-induced interstitial lung disease : a systematic review", J Clin Med, 7, pp.356~ (2018)
- Cui P, "Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy : a case-control study", Cancer Med, 7, pp.4115~4120 (2018)
- Nishino M, "Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer : a systematic review and meta-analysis", JAMA Oncol, 2, pp.1607~1616 (2016)
- Gemma A, "Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib", J Thorac Oncol, 14, pp.672~682 (2019)
- Oshima Y, "EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer", JAMA Oncol, 4, pp.1112~1115 (2018)
- Lim ZF, "Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy", J Hematol Oncol, 12, pp.134~ (2019)
- Brahmer JR, "Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors : safety, clinical activity, pharmacodynamics, and immunologic correlates", J Clin Oncol, 28, pp.3167~3175 (2010)
- Schoenfeld AJ, "Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib", Ann Oncol, 30, pp.839~844 (2019)
- Moya-Horno I, "Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer(NSCLC)", Ther Adv Med Oncol, 10, pp.1758834017745012~ (2018)
- Lin JJ, "Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer", J Thorac Oncol, 14, pp.135~140 (2019)
- Longoria TC, "Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma", Expert Opin Drug Metab Toxicol, 12, pp.1247~1253 (2016)
- Mizoguchi K, "Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations", Cancer Chemother Pharmacol, 78, pp.377~382 (2016)
- Palma DA, "Predicting radiation pneumonitis after chemoradiation therapy for lung cancer : an international individual patient data meta-analysis", Int J Radiat Oncol Biol Phys, 85, pp.444~450 (2013)
- Nakahama K, "Association between imaging findings of airway obstruction adjacent to lung tumors and the onset of interstitial lung disease after nivolumab", In Vivo, 32, pp.887~891 (2018)
- Katsui K, "Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer : a retrospective analysis", BMC Cancer, 19, pp.1144~ (2019)
- Rodrigues G, "Definitive radiation therapy in locally advanced non-small cell lung cancer : executive summary of an American Society for Radiation Oncology(ASTRO)evidence-based clinical practice guideline", Pract Radiat Oncol, 5, pp.141~148 (2015)
- Fukihara J, "Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small-cell lung cancer who received programmed death 1 inhibitors", Clin Lung Cancer, 20, pp.442~450 (2019)
- Shinno Y, "The long half-life of programmed cell death protein 1 inhibitors may increase the frequency of immunerelated adverse events after subsequent EGFR tyrosine kinase inhibitor therapy", JTO Clin Res Rep, 1, pp.100008~ (2020)